Skip to main content
رجوع
TVTX logo

Travere Therapeutics, Inc.

جودة البيانات: 100%
TVTX
NASDAQ Healthcare Biotechnology
KWD 27.75
▲ KWD 0.91 (3.39%)
القيمة السوقية: 2.56B
نطاق اليوم
KWD 27.20 KWD 28.29
نطاق 52 أسبوعًا
KWD 12.91 KWD 42.13
حجم التداول
1,165,403
متوسط 50 يوم / 200 يوم
KWD 29.58 / KWD 25.90
الإغلاق السابق
KWD 26.84

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -50.9 0.4
P/B 22.3 2.9
ROE % -57.8 3.7
Net Margin % -10.2 3.9
Rev Growth 5Y % 38.9 10.0
D/E 2.9 0.2

السعر المستهدف للمحللين

Hold
KWD 49.000 +76.6%
مكرر الربحية المستقبلي
73.6
ربحية السهم المستقبلية
KWD 0.377
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
700 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 5.072
KWD 3.974 – KWD 6.322
1.5 B 2
FY2029 KWD 4.072
KWD 3.190 – KWD 5.075
1.3 B 4
FY2028 KWD 3.408
KWD 2.017 – KWD 5.752
1.1 B 6

النقاط الرئيسية

Revenue grew 38.90% annually over 5 years — strong growth
Debt/Equity of 2.86 — high leverage
Generating 37.78M in free cash flow
PEG of 0.79 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 71.55%
Capital efficient — spends only 0.00% of revenue on capex

النمو

Revenue Growth (5Y)
38.90%
Revenue (1Y)110.45%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-57.80%
ROIC-10.62%
Net Margin-10.24%
Op. Margin-12.80%

الأمان

Debt / Equity
2.86
Current Ratio2.74
Interest Coverage-5.85

التقييم

P/E Ratio
-50.93
P/B Ratio22.29
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 110.45% Revenue Growth (3Y) 83.81%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 38.90% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 490.73M Net Income (TTM) -50.26M
ROE -57.80% ROA -8.30%
Gross Margin 85.51% Operating Margin -12.80%
Net Margin -10.24% Free Cash Flow (TTM) 37.78M
ROIC -10.62% FCF Growth (3Y) N/A
Safety
Debt / Equity 2.86 Current Ratio 2.74
Interest Coverage -5.85 Dividend Yield 0.00%
Valuation
P/E Ratio -50.93 P/B Ratio 22.29
P/S Ratio 5.22 PEG Ratio 0.79
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.56B Enterprise Value 2.80B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 490.73M 233.18M 145.24M 109.46M 131.84M
Net Income -50.26M -321.55M -111.40M -278.48M -180.09M
EPS (Diluted) -0.56 -4.08 -1.50 -4.37 -3.01
Gross Profit 419.65M 225.43M 133.79M 105.04M 128.02M
Operating Income -62.82M -323.83M -388.14M -319.81M -199.43M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 605.19M 594.13M 788.91M 672.59M 776.63M
Total Liabilities 490.36M 535.05M 588.10M 629.73M 474.52M
Shareholders' Equity 114.83M 59.08M 200.81M 42.85M 302.11M
Total Debt 328.73M 401.58M 404.78M 407.49M 261.99M
Cash & Equivalents 93.04M 58.54M 58.18M 61.69M 165.75M
Current Assets 437.57M 416.70M 616.78M 486.44M 582.83M
Current Liabilities 159.90M 200.75M 177.91M 142.16M 124.09M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#1 of 146
91

النشاط الأخير

دخل Full Throttle
Mar 24, 2026